Spravato® is the first and only FDA-approved medicine that has been shown to reduce depressive symptoms within 24 hours.1
Spravato®
Typically taken with an oral antidepressant
Significant reduction of depressive symptoms at four weeks (compared to those who received a placebo and oral antidepressant)
Covered by most major insurance companies for the treatment for depressive disorders
Talk with your provider if you have a history of drug or alcohol abuse
Nasal spray you self-administer under the supervision of a healthcare provider
SPRAVATO® (eskatamine) is a FDA approved nasal spray used to help patients with treatment-resistant depression (TRD). SPRAVATO (eskatamine) is self-administered under the supervision of a healthcare provider and is taken along with an oral antidepressant.
Benefits of Spravato?
Rapid relief of depressive symptoms
Beneficial for those who haven’t responded well to antidepressant medications
Covered by most insurance for the management of treatment resistant depression
What is Spravato?
Spravato (eskatamine) has proven to be a beneficial approach for treatment-resistant depression and mood disorders. Spravato is known for its rapid-acting antidepressant effects, often within hours or days, compared to traditional antidepressants.
Treatments require in office observation for 2 hours for medical monitoring before the client can return home. Clients must have transportation arranged after appointments, they may not drive themselves. By the following morning, individuals who have undergone treatment may resume their normal activities.
How It Works
The initial course of SPRAVATO (eskatamine) treatment is twice a week for four weeks then generally once a week. It can be continued 2 to 4 times a month for maintenance, for as long as it is needed. After treatment, it requires in-office observation for 2 hours for medical monitoring before you can return home. Once administered, you should not be driving or operating any equipment for the remainder of the day. For your safety, we require you have someone assist you in transporting to and from your appointments. After a good night’s sleep you can drive and return to normal activities.
For more information about SPRAVATO (eskatamine) please visit:
Spravato Treatment Process
SPRAVATO® helped Nicole’s treatment-resistant depression.
Now, she’s resuming her education and sharing her story.
Allison’s son tried many oral antidepressants without relief.
Now, because of SPRAVATO®, Allison’s son is starting to feel like himself again.
SPRAVATO® Resources
Frequently Asked Questions
-
Spravato® (esketamine) nasal spray contains a derivative of ketamine. SPRAVATO® is an FDA-approved nasal spray for treatment-resistant depression; it is also approved to treat depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions. Ketamine IV infusion has not been FDA-approved to treat mental health issues and is not typically covered by insurance for depression treatment.
-
Spravato® nasal spray works differently than other medications prescribed to target depressive symptoms. Most conventional oral antidepressants act to increase levels of serotonin, dopamine, or norepinephrine in the brain. Spravato, however, works differently by enhancing the activity of glutamate in mood-regulating regions of the brain. This action allows it to be uniquely effective in some treatment situations where other depressive medication options have failed. The main ingredient in Spravato (esketamine) is also believed to help create connections between brain cells in areas that many people who struggle with depression lack.
-
Spravato was approved by the FDA in 2019 for the treatment of adults with depression. It is used in conjunction with a daily oral antidepressant to treat Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD).
-
Spravato is covered by most major insurance companies, including Medicare.
-
Patients will be monitored for 2 hours after treatment completion before being released and will need to plan for transportation home. Driving or operating machinery should not take place until after a full night of sleep post-treatment. The initial therapy begins with two treatments per week for four weeks. After four weeks, you will be re-evaluated by our psychiatrist and an individualized treatment plan will be tailored to your behavioral health needs, with treatments often tapered down for maintenance.
1. SPRAVATO® [Prescribing Information]. Titusville, N.J., Janssen Pharmaceuticals, Inc. July 2020.